Skip to main content

InvestorNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Presents Sleep Apnea Study Results at Annual SLEEP 2022 Event

Vivos Therapeutics (NASDAQ: VVOS), a revenue-generating medical technology company focused on developing innovative treatments for patients suffering from dentofacial abnormalities and/or mild to moderate obstructive sleep apnea (“OSA”) and snoring in adults, shared results from its retrospective study during SLEEP 2022, the annual meeting of the Associated Professional Sleep Societies. Vivos Medical Advisory Board member Dr. Seth Heckman presented at the conference on June 6, 2022; his presentation was titled “Non-Surgical Maxillary Expansion Using a Novel Oral Appliance System.” According to the announcement, the presentation showed results from 786 patients who were treated with Vivos’ customized, proprietary oral appliance therapy, which the company calls Complete Airway Repositioning and/or Expansion (“CARE”) therapy.. The patients were treated for dentofacial abnormalities and/or mild to moderate OSA and snoring. Heckman noted that study participants reported statistically significant increases in both transpalatal widths (4.%) and airway volumes (11.1%), indicating that use of these devices could result in maxillary and airway expansion, which are both key components of healthy breathing. The study results also showed that some patients reported a decrease in their Apnea Hypopnea Index (“AHI”),  a scale that measures sleep apnea severity, by more than 50%. “In our published studies and presentations, we’ve shown that as many as 80% of OSA patients using our devices with a trained dentist dramatically improve their AHI scores, and as high as 34% of patients are restored to normal breathing and sleep patterns,” said Vivos chair and CEO Kirk Huntsman in the press release. “Moreover, our data has shown no further intervention has been required, which is a critical differentiating factor between our appliance therapy and other treatments for OSA. In fact, we know of no other OSA treatment that can match this. Sleep apnea contributes to multiple physical and mental health issues that most patients don’t even realize, which may include high blood pressure/hypertension, heart failure, stroke, coronary artery disease, depression/anxiety and many other life-threatening illnesses. With innovative modern technologies like CARE, highly invasive, lifetime inventions like CPAP machines and surgeries may no longer be the only answer for patients in need.”

To view the full press release, visit

About Vivos Therapeutics Inc.

Vivos Therapeutics is a medical technology company focused on developing and commercializing innovative diagnostic and treatment methods for patients suffering from dentofacial abnormalities or mild-to-moderate obstructive sleep apnea (“OSA”) as well as snoring in adults. The Vivos Method represents the first clinically effective, nonsurgical, noninvasive, nonpharmaceutical and cost-effective solution and has proven effective in the treatment of an estimated 27,000 patients worldwide by more than 1,500 trained dentists. The Vivos Method includes the Vivos Complete Airway Repositioning and/or Expansion (CARE) appliance therapy and associated protocols that alter the size, shape and position of the tissues that comprise a patient’s upper airway. The Vivos Method opens airway space and may significantly reduce symptoms and conditions associated with mild to moderate OSA, such as lowering Apnea Hypopnea Index scores. Vivos also markets and distributes SleepImage diagnostic technology under its VivoScore program for Home Sleep Testing in adults and children. The Vivos Integrated Practice (VIP) program offers dentists training and other value-added services in connection with using The Vivos Method. For more information about this company, visit  

NOTE TO INVESTORS: The latest news and updates relating to VVOS are available in the company’s newsroom at

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.

As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.

For more information, please visit

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published:

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office

InvestorWire is part of the InvestorBrandNetwork.

Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.